tbuckley/cabot-search huggingface dataset:
Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.
Authors: J O Armitage, J M Vose, J Linder, D Weisenburger, D Harrington, J Casey, P Bierman, S Sorensen, M Hutchins, D F Moravec
Journal: Journal of Clinical Oncology (1989)

We performed a prospective study of the clinical significance of immunophenotype in 110 patients with aggressive non-Hodgkin's lymphoma (NHL) treated by oncologists in the Nebraska Lymphoma Study Group between October 1982 and May 1986. All patients were immunophenotyped from biopsies performed before therapy was administered. The patients were treated with a uniform protocol of radiotherapy for minimal nonbulky, stage I or II disease (seven patients) or a single, six-drug chemotherapy regimen cyclophosphamide, doxorubicin, procarbazine, bleomycin, vincristine, and prednisone (CAP-BOP) in patients with more extensive disease (103 patients). Ninety-one patients (83%) had B-cell lymphoma and 19 patients (17%) had T-cell lymphoma. The histologic diagnosis of diffuse mixed-cell lymphoma was significantly associated with T-cell immunophenotype (45% v 5%; P less than .001), and the diagnosis of diffuse large-cell lymphoma was significantly associated with B-cell immunophenotype (40% v 5%; P = .006). However, no significant difference in frequency of prognostic variables such as age, stage, systemic symptoms, tumor bulk, serum lactic dehydrogenase, or performance status was found between the B-cell and T-cell groups. Patients with B-cell NHL had a slightly higher complete remission rate (74% v 53%; P = NS), similar durability of complete remission (75% v 70% at 3 years; P = NS), and a slightly but not significantly better overall survival (50% v 41% at 3 years; P = NS). The slight advantage in response rate and survival for B-cell patients was related to a very poor outcome for patients with stage IV T-cell NHL. For patients with stage I to III disease, neither the complete remission rate (B-cell, 82% v T-cell, 91%; P = NS) nor overall survival (3-year survival for B cell, 58% v T cell, 73%; P = NS) were significantly different. However, with stage IV disease B-cell patients fared far better than those with T-cell NHL for both complete remission rate (67% v 0%; P = .002) and overall survival (3-year survival, 44% v 0%; P = .002). Immunophenotyping intermediate- and high-grade NHL allowed identification of a subgroup of patients who had a very poor prognosis with this treatment approach and for whom alternate therapy might be considered.
A Phase II study of the efficacy and tolerability of Lapatinib in patients with advanced hepatocellular carcinomas.
Authors: Joseph Markowitz, Charis Eng, Wolfgang Sadee, Nyla Heerema, Xiaobai Li, Angela Campbell, Kristy Culler, Bert O'Neil, Ruey-min Lee, Mark Zalupski, Janet Dancey, Michael Grever, Miguel Villalona-Calero, Tanios Bekaii-Saab
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

LB-306 

Abstract LB-306 has been selected for inclusion in the AACR’s Annual Meeting press program and is therefore embargoed until date and time of press briefing or scientific presentation, whichever comes first. The abstract is scheduled for scientific presentation and will be posted to this site at or after the following date and time: 4/15/2008 1:00 PM.
Early Intervention for Psychotic Disorders
Authors: Vinod H. Srihari, Anant Jani, Muir Gray
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Radiotherapy vs. temozolomide in the treatment of patients with lung cancer and brain metastases: A nordic randomized phase II study
Authors: G. Wagenius, O. Brodin, J. Nyman, G. Greim, G. Hillerdal, H. Riska, S. Sundström, B. Grönberg, M. Wang, H. Garmo
Journal: Journal of Clinical Oncology (2006)

7136 Background: Metastasis to the brain is the most common intracranial tumour and 20–40% of all cancer patients will develop brain metastases. Lung cancer is the most common primary tumour and compose of 40%-50% of all brain metasases. As the survival in many malignancies increases, brain metastases will be an increasing problem. It is therefore important to find new treatment options. The aim of this study was primary to study quality of life and to compare radiotherapy and Themozolomide in that context. Methods: Inclusion criterias were confirmed small cell or non-small cell lung cancer, multiple brain metastases, PS 0–2, no previous radiotherapy to the brain. Previous chemotherapy was allowed. Patients were randomized to arm A (radiotherapy 30 Gy over 10 fractions) or arm B (Temozolomide 200 mg/m 2 day 1–5, new cycle on day 29). Quality of life (QoL) was measured with a general cancer module, EORTC QLQ-C30, and a brain cancer specific module, BCM20. The primary end-point was the proportion of patients in each treatment arm with maintained or better QoL score at 8 weeks compared to the base line evaluation. In this first analysis exclusion rate from the study at 8 weeks was used as a surrogate end-point. Results: 208 patients were included, 104 in arm A and 104 in arm B. 36 (17%) squamous cell, 97 (47%) adenocarcinomas, 10 (5%) large cell, 23 (11%) undifferentiated and 42 (20%) small-cell lung cancer were included. 93 (45%) patients were chemonaive. At 8 weeks, 79 patients were excluded from the study, 51 (49%) from the temozolomide arm and 28 (27%) from the radiotherapy arm. 53% of the patients with squamous cell carcinoma were excluded compared to 40% of small cell lung cancer, 33% of adenocarcinomas and 27% of large cell carcinomas. The exclusion rate at 8 weeks was higher among patients with symptoms at randomization compared to patients without symptoms. There were no difference in exclusion rate when comparing number or size of the metastases. Conclusion: The exclusion rate at 8 weeks was higher in the temozolomide arm compared to the radiotherapy arm. Histopathology and symptoms at randomization seems to be factors influencing the exclusion rate whereas number or size of metastases does not. Survival and quality of life data will be presented at the meeting. No significant financial relationships to disclose.
The role of patient advocates in clinical trials: Perspectives from investigators and advocates in the Cancer and Leukemia Group B (CALGB).
Authors: M. L. Katz, L. Archer, J. M. Peppercorn, S. Kereakoglow, D. Collyar, H. J. Burstein, R. L. Schilsky, A. H. Partridge
Journal: Journal of Clinical Oncology (2010)

6148 Background: Patient advocates are increasingly involved in cooperative group trials, single-institution cancer programs, and peer review of research applications. We sought to evaluate the role and value of advocates from the perspective of CALGB advocates and lead cooperative group investigators. Methods: We developed an online survey for current and past (within 5 years) advocates and investigators (committee chairs, cochairs, study chairs, and protocol coordinators). Email reminders were sent to maximize response rates. Fisher's exact test were performed; p < 0.05 was considered significant. Results: Response rates were 72.7% (16/22) for advocates, 56.4% (102/181) for investigators. Significant differences were: 100% of advocates vs. 72% of investigators reported the clinical trial process benefited from advocate involvement (p = 0.019); advocates were more likely than investigators to believe that advocates contribute substantially to protocol development, cultural appropriateness, and accrual (p < 0.001); and to perceive advocate involvement in concept development and protocol review as valuable (p < 0.01). One-third of advocates and investigators reported gaps in advocate knowledge and suggested additional clinical trials training was needed. To improve clinical trials, advocates suggested earlier involvement in protocol development and additional support from investigators, and investigators recommended improving advocate selection and communication skills training. Conclusions: The majority of advocates and investigators perceive benefits from advocate involvement in the clinical trials process; advocates placed more value on the role than investigators. Strategies to improve advocacy training and advocate-investigator communication may further enhance the role of advocates, and further studies that clarify the role of advocates in the prioritization and development of protocol, consent, and education materials, and on patient accrual, are warranted. No significant financial relationships to disclose.
Abstract 12318: Prevalence of Atrial Fibrillation in Patient With Celiac Disease
Authors: deepak J pattanshetty, Rama Dilip Gajulapalli
Journal: Circulation (2014)

Background: Inflammation is an established risk factor for Atrial Fibrillation (AF). Celiac Disease (CD) is a systemic autoimmune inflammatory disease. Given the nature of the CD, this group could be at high risk for developing AF. We aim to evaluate the prevalence of atrial fibrillation in patients with Celiac disease. Methods: Electronic health records (01/1999 to 09/2013) from 13 different healthcare systems were obtained utilizing a HIPAA-compliant, patient de-identified web application (Explore; ExplorysInc). Among a total of 22, 385,340 patients, 24,530 were diagnosed with CD. The remaining 22,360,810 patients without CD served as the control group. The demographics and comorbidities are abstracted for comparison. Results: There was a significantly higher prevalence of AF among CD compared to those without CD [5.6 % vs. 2.8%, p &lt;0.0001)] with the odds ratio being 2.04 (95% CI 1.9 to 2.2). After excluding the patients with coronary artery disease in both groups, the prevalence of AF was still higher among 2.9 % in celiac disease group compared to control group (2.9 % vs. 1.4%, p &lt;0.0001) with odds ratio being 2.05 (95% CI 1.9 to 2.2). Patient characteristics are compared in table 1. Conclusions: There was a two fold increase in the prevalence of AF in patients with celiac disease compared to those of control group , which could well be due to the autoimmune disease causing systemic inflammation. Further prospective studies are needed to study the association in detail.
Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.
Authors: Lawrence E. Flaherty, James Moon, Michael B. Atkins, Ralph Tuthill, John A. Thompson, John T. Vetto, Frank G. Haluska, Alberto S. Pappo, Jeffrey Alan Sosman, Bruce G. Redman, Antoni Ribas, John M. Kirkwood, Vernon K. Sondak
Journal: Journal of Clinical Oncology (2012)

8504 Background: High-dose interferon for one year (HDI) is the FDA approved adjuvant therapy for patients (pts) with high-risk melanoma (HRM). Efforts to modify IFN dose or schedule have not improved efficacy. A meta-analysis demonstrated that biochemotherapy (BCT) produced superior response rates compared with chemotherapy in pts with stage IV melanoma (Wheatley et al J Clin Oncol 25:5426, 2007). We sought to determine whether a short course of BCT would be more effective than HDI as adjuvant treatment in pts with HRM. Methods: S-0008 (an Intergroup Phase III trial) enrolled pts who were high risk (Stage III A-N2a thru Stage III C N3) and randomized them to receive either HDI or BCT consisting of dacarbazine 800 mg/m 2 day 1, cisplatin 20 mg/m 2 / days 1-4, vinblastine 1.2 mg/m 2 days 1-4, IL-2 9 MIU/m 2 /day continuous IV days 1-4, IFN 5 MU/m 2 /day sc days 1-4, 8,10,12, and G-CSF 5 ug/kg/day sc days 7-16. BCT cycles were given every 21 days x 3 cycles (9 weeks total). Pts were stratified for number of involved nodes (1-3 v ≥4), micro v macro metastasis, and ulceration of the primary. Co-primary endpoints were relapse free survival (RFS) and overall survival (OS) using a one-sided log rank test at p= 0.05. Results: 432 pts were enrolled between 8/2000 and 11/2007: 30 were ineligible or withdrew consent. Grade 3 and 4 adverse events occurred in 57% and 7% respectively of HDI pts and 36% and 40% of BCT pts. At a median f/up of 6 yrs, BCT improved RFS (p = 0.02, HR 0.77 [90% CI: 0.62 – 0.96]) with median RFS for BCT of 4.0 yrs (90% CI:1.9 – 5.9) v 1.9 yrs (90% CI: 1.4 – 2.5) and 5 yr RFS of 47% v 39%. Median OS was not different between the two arms (p = 0.49 HR 1.0 [90% CI: 0.78 – 1.27]) with median OS not yet reached for BCT v 8.4 yrs (90% CI: 4.5 – 9.3) for HDI and 5 yr survival 56% for both arms. Conclusions: In HRM pts, BCT provides a statistically significant improvement in RFS compared to HDI, but no discernable difference in OS and more grade IV toxicity. BCT represents a shorter, alternative treatment for pts with HRM, and a potential control arm and basis for future combinations in the adjuvant setting.
Radiotherapy With 4 Gy × 5 Versus 3 Gy × 10 for Metastatic Epidural Spinal Cord Compression: Final Results of the SCORE-2 Trial (ARO 2009/01)
Authors: Dirk Rades, Barbara Šegedin, Antonio J. Conde-Moreno, Raquel Garcia, Ana Perpar, Michaela Metz, Harun Badakhshi, Andreas Schreiber, Mirko Nitsche, Peter Hipp, Wolfgang Schulze, Irenaeus A. Adamietz, Darius Norkus, Volker Rudat, Jon Cacicedo, Steven E. Schild
Journal: Journal of Clinical Oncology (2016)

Purpose To compare short-course radiotherapy (RT) (4 Gy × 5) to longer-course RT (3 Gy × 10) for metastatic epidural spinal cord compression (MESCC). Patients and Methods Two-hundred three patients with MESCC and poor to intermediate expected survival were randomly assigned to 4 Gy × 5 in 1 week (n = 101) or 3 Gy × 10 in 2 weeks (n = 102). Patients were stratified according to ambulatory status, time developing motor deficits, and primary tumor type. Seventy-eight and 77 patients, respectively, were evaluable for the primary end point, 1-month overall response regarding motor function defined as improvement or no further progression of motor deficits. Other study end points included ambulatory status, local progression-free survival, and overall survival. End points were evaluated immediately after RT and at 1, 3, and 6 months thereafter. Results At 1 month, overall response rates regarding motor function were 87.2% after 4 Gy × 5 and 89.6% after 3 Gy × 10 (P = .73). Improvement rates were 38.5% and 44.2%, respectively, no further progression rates 48.7% and 45.5%, respectively, and deterioration rates 12.8% and 10.4%, respectively (P = .44). Ambulatory rates at 1 month were 71.8% and 74.0%, respectively (P = .86). At other times after RT, the results were also not significantly different. Six-month local progression-free survival was 75.2% after 4 Gy × 5 and 81.8% after 3 Gy × 10 (P = .51); 6-month overall survival was 42.3% and 37.8% (P = .68). Conclusion Short-course RT with 4 Gy × 5 was not significantly inferior to 3 Gy × 10 in patients with MESCC and poor to intermediate expected survival.
P53 overexpression is a significant factor in predicting resistance to 3rd generation aromatase inhibitors (AIs) in hormone-sensitive recurrent or advanced breast cancer
Authors: K. Kai, R. Nishimura, M. Matsuda, H. Miyayama, N. Arima
Journal: Journal of Clinical Oncology (2005)

715 Background: HER-2 positivity is an appropriate predictive factor for the resistance to tamoxifen. However our knowledge of which factors indicate the resistance to 3rd AIs in recurrent or advanced breast cancer is insufficient. In our study, we assessed the correlations between the efficacy (response rate, time to progression) of 3rd AIs and clinicopathological factors to determine the appropriate predictive factor for the resistance to 3rd AIs. Methods: We investigated the disease courses and clinicopathological factors in seventy-nine recurrent or advanced patients (pts) treated with 3rd AIs in our hospital between February 1996 and December 2004. Sixty-three of the 79 pts treated with 3rd AIs as 1st line or 2nd line endocrine therapy (Anastrozole: 47cases, Exemestane: 15, Letrozole: 1) were eligible for this retrospective study. All pts were postmenopausal with positive ER and/or PgR tumors. Forty cases were treated as 1st line endocrine therapy, and 23 cases as 2nd line therapy. Forty-eight pts had been treated with antiestrogens before 3rd AIs (44 cases for adjuvant, 4 cases for advanced disease). The clinicopathological factors included the following, dominant site (soft tissue, bone, viscera), disease free interval, MIB-1, p53, and HER-2 status. The expressions of MIB-1, p53 and HER2 were evaluated by immunostaining. The p-values less than 0.05 were regarded as significant. Results: The overall response rate (RR) of 3rd AIs was 39.7%. The median time to progression (TTP) was 8.4 months. In relation to response to 3rd AIs, the pts with p53 overexpressed tumors had a lower RR (21.4%) than those without (34.6%) (p=0.06). In relation to TTP of 3rd AIs, the pts with bone lesions had a shorter TTP than those with soft tissue lesions (p=0.05). The pts with p53 overexpressed tumors had a significantly shorter TTP (9.3±2.8 months) than those without (14.7±2.3) (p=0.04). Conclusion: p53 overexpression in recurrent or advanced breast cancer is useful in predicting the resistance to 3rd AIs. If validated by larger studies, the p53 expression may become a key factor in determining treatment strategies for postmenopausal hormone-sensitive disease. No significant financial relationships to disclose.
Ras and the cancer cell: A transforming relationship
Authors: Dafna Bar-Sagi
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

SY25-02 

Activating mutations in Ras proteins are highly prevalent in many human cancers. These mutations lock the proteins in their GTP-bound form resulting in the constitutive activation of signaling pathways that control cell proliferation, tumor survival and motility. This lecture will focus on ongoing efforts to define how the signaling activities of Ras are controlled and how such control mechanisms may contribute to tumor initiation and progression.
Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors
Authors: T. R. J. Evans, J. A. Morgan, A. D. van den Abbeele, I. R. J. McPherson, S. George, D. Crawford, J. M. Mastrullo, S. Cheng, J. A. Fletcher, G. D. Demetri
Journal: Journal of Clinical Oncology (2005)

3034 Background: BMS-354825 is a potent, orally active, inhibitor of several kinase signalling molecules including members of the SRC family of kinases, KIT, PDGFR, and BCR-ABL. This is the first study to evaluate the safety, tolerability, and pharmacologic profiles of BMS-354825 in pts with treatment-resistant GIST and other refractory solid tumors. Methods: Pts with adequate hematologic, renal, cardiac and liver function, received BMS-354825 orally BID for 5 days followed by a 2-day break, every week. Pts in alternate dose groups were treated after a fast or high-fat meal ± antacids. Pts were assessed continuously for safety. EKG monitoring was performed on days 1, 5, 26. Pharmacokinetic (PK) profiling was performed on days 1, 8, 26. Pharmacodynamic (PD) biomarkers (pSrc, pFAK, KIT and SCF) and early imaging with FDG-PET were assessed in the first week of treatment, with a PD biomarker assessment on day 26 also. Serial imaging with CT was performed at least every 8 weeks, with FDG-PET in weeks 1, 4, and 8. Results: 14 pts [M=9, F=5] ECOG PS ≤ 1 with GIST (n=9) or other solid tumors (5) were treated in 1 of 3 escalating dose levels: 35, 50, or 70 mg BID. Toxicity included clinically insignificant grade 3 lymphopenia (2 pts), grade 3 anorexia (1), and elevation of Alk Phosph to grade 3 (1). No dose-limiting toxicity (DLT) has been observed. At 35mg BID, the PK profile in fasting pts resembles the experience in fasting pts with hematologic malignancies, but food and GI pH show an effect on PK parameters [mean T1/2 = 1.3 hrs (fasted); 4.6 hrs (after food)]. There have been no objective responses on CT, but activity has been noted as mixed responses on FDG-PET, resolution of GIST-associated ascites (1 pt) and continued study treatment for ≥ 3 months in two GIST pts. Conclusions: BMS-354825 can be safely administered at doses of up to 70mg BID on a 5-days on, 2-days off, weekly schedule. There have been no DLTs and dose escalation continues. Correlative science studies of tumor biopsies and early FDG-PET and CT imaging results will be reported. The clinical benefits noted in a subset of pts with treatment-resistant GIST is encouraging. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb Bristol-Myers Squibb